1-15 of 844
The New Era of Targeted Therapy for Myasthenia Gravis
NeuroFrontiersThe New Era of Targeted Therapy for Myasthenia Gravis
Shruti Raja, MD, MHS
Immunologic Phenotyping: The Future of Personalized MG Care
NeuroFrontiersImmunologic Phenotyping: The Future of Personalized MG Care
Shruti Raja, MD, MHS
Shruti Raja, MD, MHS
New Therapies, New Strategy: Rethinking MG Inpatient Care
NeuroFrontiersNew Therapies, New Strategy: Rethinking MG Inpatient Care
Qihua Fan, MD
Navigating Emerging Treatment Options in MG
NeuroFrontiersNavigating Emerging Treatment Options in MG
Qihua Fan, MD
Qihua Fan, MD
- advertisement
More Than a Myopathy: The Lived Experience of TK2d
NeuroFrontiersMore Than a Myopathy: The Lived Experience of TK2d
Outcome Measures Capture Progression in Late-Onset TK2d
NeuroFrontiersOutcome Measures Capture Progression in Late-Onset TK2d
Untreated Thymidine Kinase 2 Deficiency: Mapping the Progressive Disease Course
AudioAbstractsUntreated Thymidine Kinase 2 Deficiency: Mapping the Progressive Disease Course
Ryan Quigley
The Spectrum of Neurologic Conditions in Sjögren's Patients
Living RheumThe Spectrum of Neurologic Conditions in Sjögren's Patients
Nancy Carteron, MD
James Swanson, PhD
James Swanson, PhD
- advertisement
ADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
NeuroFrontiersADHD Medication Dose-Effect Patterns Vary by Age and Drug Class
ADHD Is Linked to a Broad Burden of GI Symptoms
NeuroFrontiersADHD Is Linked to a Broad Burden of GI Symptoms
Untangling ADHD from Depression, Anxiety, and Substance Use Disorder
NeuroFrontiersUntangling ADHD from Depression, Anxiety, and Substance Use Disorder
Jill RachBeisel, MD
